- Information
- AI Chat
This is a Premium Document. Some documents on Studocu are Premium. Upgrade to Premium to unlock it.
Was this document helpful?
This is a Premium Document. Some documents on Studocu are Premium. Upgrade to Premium to unlock it.
Y2 BB PBL Questions
Module: Medicine (A100)
545 Documents
Students shared 545 documents in this course
University: Queen Mary University of London
Was this document helpful?
This is a preview
Do you want full access? Go Premium and unlock all 7 pages
Access to all documents
Get Unlimited Downloads
Improve your grades
Already Premium?
PBL1: Mr Body
1. Name the neurotransmitters released by the corticostriatal and striatopallidal pathways (1 mark)
● Glutamate and GABA respectively
2. Describe the effects of D1 receptor activation on striatal efferent circuitry (2 marks)
● D1 receptor activation causes the activation of the direct pathway (½ mark) by which the GPi is
inhibited (½ mark). This causes the disinhibition of the thalamus (½ mark) and hence the activation
of the cortex (½ mark)
3. What is cognitive behavioural therapy (CBT)? (2 marks)
● It’s a behavioural and cognitive approach that looks at how we think about a situation and how this
affects the way we act (1 mark)
● Method: therapist and patient work together in changing the patient’s behaviours, their thinking
patterns or both of these, resulting in more positive thoughts (1mark)
4. List and briefly describe three long-term complications of L-DOPA therapy (3 marks)
● Motor fluctuations: include “on-off” phenomena in which sudden and dramatic fluctuations of motor
performance occur; periods of normal mobility (on) followed by sudden ‘freezing’ (off). End of dose
deterioration and delayed (or ‘no on’- freezing) responses also occur (1 mark)
● Dyskinesias: include choreiform movements (purposeless involuntary dance-like movements) and
dystonias (sustained intense muscle contractions) (1 mark)
● Neuro-psychiatric problems: hallucinations, delirium, mood changes, sleep disturbance and
nightmares (1 mark)
5. What is rotigotine and what is its route of administration? (2 marks)
● Dopamine receptor agonist (non-selective) with affinity for both D1 and D2 family receptors
● Applied transdermally as a patch
6. In Parkinson’s disease striatal dopamine signalling is gradually lost. How can this loss be monitored
using imaging? (1 mark)
● The gradual loss of dopaminergic innervation of the striatum can be monitored by imaging the
dopamine transporter, using the DaTScan (1 mark)
7. What is alpha-synuclein, where is it found and what is its link with Parkinson’s? (2 marks)
● Alpha-synuclein is a protein found in the cytoplasm in Lewy bodies (major histopathological
feature of Parkinson’s disease) (1 mark)
● Certain genes associated with alpha-synuclein (PARK1/4, SNCA gene) have been identified as a
genetic risk factor for Parkinson’s disease (1 mark)
8. Selegiline was considered to be added to Mr Body’s medication. What is the mechanism of action of
selegiline and why might this improve Mr Body’s symptoms? (2 marks)
● Selegiline is a monoamine oxidase B inhibitor (1 mark)
● MAOB breaks down dopamine so inhibiting this enzyme will increase the available levels of
dopamine in the brain (1 mark)
Why is this page out of focus?
This is a Premium document. Become Premium to read the whole document.
Why is this page out of focus?
This is a Premium document. Become Premium to read the whole document.